Edaravone suspension for oral administration

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11826352
APP PUB NO 20210251965A1
SERIAL NO

17308399

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
MITSUBISHI TANABE PHARMA CORPORATIONOSAKA-SHI OSAKA 541-8505

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Hayama, Tetsuo Osaka, JP 8 17
Hayashi, Kouji Osaka, JP 38 436
Matsuda, Munetomo Osaka, JP 11 20
Miyazawa, Tadashi Osaka, JP 12 98
Omura, Tomoyuki Osaka, JP 15 199
Takahashi, Tomohiro Osaka, JP 169 747

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 28, 2027
7.5 Year Payment $3600.00 $1800.00 $900.00 May 28, 2031
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 28, 2035
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00